Alexza Pharmaceuticals, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Alexza Pharmaceuticals, Inc.
Private Company Edition: The Novo Holdings Repair Impact Fund wants to fund another round of antimicrobial resistance efforts. Also, Atlas Venture raised a new $400m fund, Everest closed a $310m series C round and Cognition received a $78.5m grant.
The Belgian drugmaker is getting hold of a device that delivers an inhaled formulation of the anxiety drug alprazolam which can rapidly terminate an epileptic seizure 30 seconds after it has begun.
CEO Richard Pops said the company will leverage in-house expertise for internally and externally developed neuroscience assets, but partner selectively to advance its IL-2 protein in cancer.
Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.
- Other Names / Subsidiaries
- Addicere Therapeutics, Inc.